| oxaliplatin / Generic mfg. |
ZSAB-TransGOLP, NCT05156788: Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 40 | RoW | PD-1+Lenvatinib+GEMOX | Shanghai Zhongshan Hospital | Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib | 07/23 | 10/25 | | |
DurHope, NCT04945720: Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Hepatic artery infusion chemotherapy（HAIC）, Durvalumab, Durvalumab Injection | Sun Yat-sen University | Hepatocellular Carcinoma | 07/23 | 12/23 | | |
NCT05866653: Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients |
|
|
| Recruiting | 2 | 90 | RoW | lidocaine transdermal patch | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients | 07/23 | 07/23 | | |
ChiCTR2100048743: A randomized, open, multicenter phase II study of efficacy and safety comparing XELOX and a PD-1 inhibitor and a bevacizumab biosimilar drug (DAITON）with XELOX and a bevacizumab biosimilar drug (DAITON）in the first-line treatment of RAS mutated pMMR /MSS advanced colorectal cancer patients |
|
|
| Not yet recruiting | 2 | 120 | | XELOX combined with PD-1 inhibitor and bevacizumab biosimilar ;XELOX in combination with bevacizumab biosimilar | the First Medical Center of PLA General Hospital; PLA General Hospital, N/A | First-line treatment of RAS mutated PMMR /MSS advanced colorectal cancer | | | | |
NCT05406206: Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy |
|
|
| Recruiting | 2 | 27 | RoW | Fruquintinib, HMPL-013, Hepatic Arterial Infusion Chemotherapy, HAIC | Beijing Cancer Hospital | Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer | 07/23 | 10/24 | | |
NCT02399410: Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis |
|
|
| Completed | 2 | 60 | Europe | perioperative chemotherapy plus bevacizumab, cytoreductive surgery, Intraperitoneal Oxaliplatin | University Hospital, Ghent | Colorectal Neoplasms | 11/23 | 11/23 | | |
NCT03603834: Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | mFOLFOXIRI, Oxaliplatin, Irinotecan, Fluorouracil, Leucovorin | Khon Kaen University | Cholangiocarcinoma | 08/23 | 12/23 | | |
| Active, not recruiting | 2 | 20 | Europe | NALRINOX combination | Fundación de investigación HM, Syntax for Science, S.L | Resectable Pancreatic Ductal Adenocarcinoma | 08/23 | 11/23 | | |
NCT04479527: Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 34 | NA | Camrelizumab, Apatinib Mesylas | Beijing Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 12/23 | | |
NCT04908566: Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 124 | RoW | PD-1 antibody combined with FOLFIRINOX regimen, PD-1 antibody combined with SOX program | Tianjin Medical University Cancer Institute and Hospital | Locally Advanced Gastric Adenocarcinoma | 08/23 | 08/28 | | |
2018-000406-36: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) |
|
|
| Not yet recruiting | 2 | 240 | Europe | nivolumab, ipilimumab, CISPLATIN, CAPECITABINE, Fluorouracil, EPIRUBICIN, Oxaliplatin, LEUCOVORIN, Docetaxel, L01XC11, Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy | European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for the Research and Treatment of Cancer, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION | Gastric, lower esophageal or GE-junction adenocarcinoma, Stomach cancer and cancer of the lower part of the esophageus, Diseases [C] - Cancer [C04] | | | | |
ChiCTR2200062758: A multicenter Phase II study of Tislelizumab in combination with bevacizumab and chemotherapy in second-line RAS mutated metastatic colorectal cancer |
|
|
| Not yet recruiting | 2 | 100 | China | Tislelizumab ;Bevacizumab ;mFOLFOX6 ;FOLFIRI | Department of Oncology, Jiangjin Hospital affiliated to Chongqing University ; Jiangjin Hospital affiliated to Chongqing University, Beigene (Beijing) Biotechnology Co., LTD | Colorectal cancer | | | | |
NCT05546411: A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer |
|
|
| Terminated | 2 | 8 | US | mFOLFIRINOX, 5-Fluorouracil (5-FU), Adrucil, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Camptothecin-11, CPT-1, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, NIS793, Chemoradiation, Surgery | Kimberly Perez, MD, Novartis | Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma | 08/23 | 10/23 | | |
NCT05048524: Peri-operative SLOG for Localized Pancreatic Cancer |
|
|
| Recruiting | 2 | 64 | RoW | S-1, leucovorin, oxaliplatin and gemcitabine | National Health Research Institutes, Taiwan | Pancreatic Ductal Adenocarcinoma, Pancreas Cancer | 08/24 | 08/25 | | |
MSCRT, ChiCTR1800016916: Preoperative Modified Short-Course Chemoradiotherapy in Middle-lower Locally Advanced Rectal Cancer: An Open-Label, Randomized, Parallel Controlled, Phase II trial |
|
|
| Not yet recruiting | 2 | 132 | | patients receive 1cycle of XELOX before concurrent capecitabine-based modified short-course radiotherapy, and after msCRT, another 3 cycles of XELOX as neoadjuvant chemotherapy would be given before TME surgery. ;concurrent capecitabine-based long-course radiotherapy, TME surgery and 4 cycles of XELOX as adjuvant chemotherapy. | Affiliated Hospital of Guangdong Medical University; Level of the institution：, IIS | Middle-lower Locally Advanced Rectal Cancer | | | | |
NCT04808791: iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Completed | 2 | 7 | Canada | Irinotecan, Camptosar, Oxaliplatin, Eloxatin, TAS 102 (Trifluridine/Tipiracil), Lonsurf | AHS Cancer Control Alberta | Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma | 07/23 | 07/23 | | |
| Completed | 2 | 77 | Europe | DONEPEZIL, PLACEBO | University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive | Digestive Oncology, Supportive Care | 01/24 | 01/24 | | |
NCT05519202: Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer |
|
|
| Not yet recruiting | 2 | 47 | NA | S-1,Oxaliplatin, Penpulimab, SOX and Penpulimab | The Central Hospital of Lishui City | Gastric Cancer | 08/23 | 08/24 | | |
NCT05451290: Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 30 | RoW | Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur, surgery | First Affiliated Hospital of Zhejiang University | Advanced Biliary Tract Carcinoma | 08/23 | 09/25 | | |
NEO-Nal- IRI, NCT03483038: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 45 | US | Liposomal Irinotecan, ONIVYDE, FOLFOX regimen | University of Florida, Ipsen | Pancreatic Adenocarcinoma | 09/23 | 12/24 | | |
NCT04191343: Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen |
|
|
| Recruiting | 2 | 20 | RoW | Toripalimab injection combined with GEMOX | Zhejiang Cancer Hospital | Advanced Biliary Tract Tumors | 09/23 | 06/24 | | |
NCT05493332: HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC |
|
|
| Not yet recruiting | 2 | 93 | NA | HAIC(FOLFOX), Hepatic Artery Infusion Chemotherapy, FOLFOX, Oxaliplatin, Leucovorin, Fluorouracil, Toripalimab, Donafenib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hepatocellular Carcinoma | 09/23 | 09/24 | | |
NCT05594381: A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. |
|
|
| Not yet recruiting | 2 | 90 | NA | Sintilimab, Oxaliplatin, Tegafur, Radical gastrectomy with D2 lymph node dissection | The First Affiliated Hospital with Nanjing Medical University, Innovent Biologics (Suzhou) Co. Ltd., Nanjing Geneseeq Technology Inc | Gastric Cancer | 09/23 | 10/25 | | |
Bohème, NCT05412706: Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy |
|
|
| Withdrawn | 2 | 46 | NA | Niraparib, Zejula | Ospedale Policlinico San Martino, CRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San Martino, Laboratory Molecular Oncology Candiolo Cancer Institute IRCCS - Candiolo (Torino) | Metastatic Colorectal Cancer | 09/23 | 09/23 | | |
| Active, not recruiting | 2 | 52 | RoW | Camrelizumab, SHR-1210, Oxaliplatin, Tegafur gimeracil oteracil potassium capsule | Yu jiren | Gastric Cancer Stage III | 09/23 | 09/25 | | |
ChiCTR2000038258: A Multicentre Randomised Phase II Study of mFOLFOXIRI Versus mFOLFOX6 in Combination With Bevacizumab or Cetuximab as First-Line Treatment for Patients With Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 450 | | mFOLFOXIRI combined with Bevacizumab/Cetuximab ;mFOLFOX6 combined with Bevacizumab/Cetuximab | The Third Affiliated Hospital of Kunming Medical University; Third Affiliated Hospital, Kunming Medical University, Self-raised | Colorectal cancer | | | | |
NeoRacing, NCT05161572: Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 152 | RoW | Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab, Concurrent chemoradiation, D2/R0 gastrectomy | Fudan University | Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy, Immunotherapy, Gastrectomy, Adenocarcinoma, Adjuvant Therapy | 09/23 | 09/26 | | |
NCT05536102: The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) |
|
|
| Recruiting | 2 | 38 | RoW | PLD, Pegylated Liposomal Doxorubicin, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Tislelizumab, BGB-A317 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Gastric Cancer | 09/23 | 09/27 | | |
IMPROVE-IT, NCT03748680: IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer |
|
|
| Recruiting | 2 | 64 | Europe | Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy, Intensified Follow-up Schedule | Karen-Lise Garm Spindler | Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemotherapy, Progression Free Survival | 10/23 | 10/25 | | |
| Recruiting | 2 | 74 | Europe | Fluorouracil, Calcium folinate, Oxaliplatin, Bevacizumab, Capecitabine, Tocotrienol, Placebo | Vejle Hospital | Colorectal Cancer Metastatic | 10/24 | 10/24 | | |
GABRINOX-ART, NCT04570943: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 103 | Europe | Gabrinox, MRI-GUIDED STEREOTACTIC RADIOTHERAPY | Institut du Cancer de Montpellier - Val d'Aurelle | Locally Advanced Pancreatic Adenocarcinoma | 01/28 | 06/30 | | |
TORCH, NCT04518280: Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 130 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Xeloda, Oxaliplatin, Short-course radiotherapy | Fudan University | Locally Advanced Rectal Cancer | 10/23 | 12/25 | | |
NCT05241574: Planned Non-operative Management for Rectal Cancer |
|
|
| Recruiting | 2 | 23 | Europe | Radiotherapy boost, Additional consolidation chemotherapy | Maria Sklodowska-Curie National Research Institute of Oncology | Rectal Cancer | 10/23 | 10/23 | | |
N-PRC, NCT05576480: SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 55 | NA | Short-course radiotherapy, Penpulimab, PD-1 monoclonal antibody, CAPEOX, Capecitabine and oxaliplatin, TME surgery | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rectal Cancer, Locally Advanced | 10/23 | 12/26 | | |
NCT06284746: Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Tirolizumab+SOX/XELOX, SOX/XELOX | Lin Chen | Locally Advanced Gastric Carcinoma, HER2 Negative, Efficacy, Safety | 04/25 | 07/25 | | |
NCT02037048: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 63 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, paclitaxel, Anzatax, Asotax, TAX, Taxol | Case Comprehensive Cancer Center | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer | 03/22 | 10/25 | | |
B2019-148, NCT04127227: Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type |
|
|
| Recruiting | 2 | 34 | RoW | sintilimab,pegaspargase,gemcitabine,oxaliplatin | Sun Yat-sen University | NK/T Cell Lymphoma Nos | 10/23 | 10/23 | | |
NCT06389760: Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Nimotuzumab, Taixinsheng, mFOLFIRINOX | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) |
|
|
| Terminated | 2 | 29 | RoW | Atezolizumab, Tecentriq, Tiragolumab, Oxaliplatin, Capecitabine | Hoffmann-La Roche | Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 11/23 | 11/23 | | |
OPRA, NCT02008656: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management |
|
|
| Active, not recruiting | 2 | 358 | US | Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin, Capecitabine (Xeloda®), intensity modulated radiotherapy (IMRT), Quality of Life Questionnaires, DRE-Endoscopy | Memorial Sloan Kettering Cancer Center, Colon and Rectal Surgery Inc., The Cleveland Clinic, John Muir Health, Oregon Health and Science University, St. Joseph Hospital of Orange, University of California, Irvine, University of California, San Francisco, University of Chicago, University of South Florida, University of Vermont, University of Washington, Medstar Health Research Institute, Washington University School of Medicine, Creighton University Medical Center, The Methodist Hospital Research Institute, University of Rochester, University of Virginia, St. Paul's Hospital, St. Joseph, Florida, Cleveland Clinic Florida, University of Colorado, Denver, University of Michigan | Rectal Cancer | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 58 | US | APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days | University of Texas Southwestern Medical Center, Apexigen America, Inc. | Locally Advanced Rectal Adenocarcinoma | 09/25 | 09/25 | | |
NCT03861702: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: |
|
|
| Active, not recruiting | 2 | 28 | US | FOLFOX regimen, Liposomal Irinotecan, nal-Irinotecan | Nelson Yee, Ipsen | Locally Advanced Pancreatic Carcinoma(LAPC) | 08/23 | 08/24 | | |
NCT05047991: Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 153 | NA | Irinotecan Liposome Injection, Fluorouracil, Leucovorin, Oxaliplatin, Nab paclitaxel, Gemcitabine | CSPC Ouyi Pharmaceutical Co., Ltd. | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | 11/23 | 11/24 | | |
NCT06134193: Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 41 | NA | HAIC, Surufatinib, Tislelizumab | Wuhan Union Hospital, China | Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer, Surufatinib, Angiogenesis Inhibitors, Tislelizumab, Antineoplastic Agents, Immunological, Immunotherapy | 06/24 | 06/25 | | |
NCT06154538: Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 170 | RoW | Cadonilimab, 1, FOLFOX regimen | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Locally Advanced Colorectal Carcinoma | 11/26 | 11/28 | | |
NCT03800693: 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers |
|
|
| Recruiting | 2 | 60 | US | Fluorouracil, 5-FU, Carac, Ribofluor, Leucovorin, Folinic acid, Oxaliplatin, Eloxatin | Emory University, Hematology/Oncology Pharmacy Association, University of Pittsburgh | Malignant Digestive System Neoplasm | 11/24 | 11/24 | | |
NCT06148402: Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Fruquintinib plus camrelizumab and capecitabine | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unresectable/Metastatic Colorectal Cancer | 12/25 | 06/26 | | |
| Recruiting | 2 | 42 | RoW | Short-course radiotherapy, RT, mFOLFOX6, Consolidation chemotherapy | National Cheng-Kung University Hospital | Rectal Cancer | 11/26 | 11/30 | | |
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. |
|
|
| Recruiting | 2 | 90 | RoW | Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001 | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 12/27 | | |
NCT06134765: Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 89 | RoW | Bemalenograstim alfa, F-627 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Pancreatic Cancer | 10/24 | 03/25 | | |
NCT00335816: Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer |
|
|
| Active, not recruiting | 2 | 248 | Canada, US | fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy, laboratory biomarker analysis, DNA analysis, polymerase chain reaction, PCR, immunohistochemistry staining method, immunohistochemistry | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Colorectal Cancer | 12/24 | 12/24 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Active, not recruiting | 2 | 177 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 262 | Europe | Nivolumab, Ipilimumab, mFOLFOX, FLOT | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Adenocarcinoma of the Stomach, GastroEsophageal Cancer | 12/23 | 03/24 | | |
NCT04668976: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma |
|
|
| Recruiting | 2 | 100 | US | Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab) | Benaroya Research Institute, Virginia Mason Hospital/Medical Center | Colorectal Cancer, Cholangiocarcinoma | 12/23 | 12/24 | | |
NCT04863430: Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach |
|
|
| Recruiting | 2 | 41 | RoW | Apatinib, Apatinib Mesylate Tablets, Oxaliplatin, Oxaliplatin for Injection, S1, Tegafur Gimeracil Oteracil Potassium Capsule | Peking University | Gastric Cancer | 12/23 | 12/25 | | |
NCT04969029: Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations |
|
|
| Recruiting | 2 | 30 | RoW | Tirelizumab | Tianjin Medical University Cancer Institute and Hospital | Immunotherapy, Adjuvant Therapy, Colon Cancer, MSI-H | 12/23 | 12/24 | | |
| Recruiting | 2 | 40 | US | FOLFOX/ nal-IRI, Paclitaxel, Abraxane®., Carboplatin, Paraplatin, Proton Radiation Therapy | Massachusetts General Hospital, Ipsen | Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer | 12/23 | 12/27 | | |
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx |
|
|
| Recruiting | 2 | 120 | RoW | AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unresectable Metastatic Colorectal Cancer | 12/23 | 06/24 | | |
DoHAICs, NCT05166772: Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | NA | Donafenib, Sintilimab, HAIC | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma | 12/23 | 12/24 | | |
NCT05166239: HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT |
|
|
| Recruiting | 2 | 66 | RoW | HAIC, Lenvatinib 1, PD-1 Inhibitors, PD-1, Lenvatinib 2, PD-1 inhibitors 2 | Peking University | Hepatocellular Carcinoma, Portal Vein Thrombosis | 12/23 | 12/24 | | |
| Recruiting | 2 | 23 | US | Nivolumab, Opdivo, Capecitabine, Xeloda, Oxaliplatin | Kidney Cancer Research Bureau | Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification | 12/23 | 12/24 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
NCT05797883: FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | FOLFOX/FOLFIRI | China Medical University, China | Unresectable or Metastatic Colorectal Cancer | 12/23 | 12/24 | | |
CCGLC-011, NCT06187961: Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Lenvatinib plus cadonilimab, levima plus cadonilimab | Tongji Hospital, Geneplus-Beijing Co. Ltd. | Hepatocellular Carcinoma Non-resectable | 12/25 | 06/26 | | |
NCT06383559: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 2 | 39 | RoW | Lenvatinib and Sintilimab | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 07/26 | 09/26 | | |
UNION PRECISION-I, NCT06234007: Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study |
|
|
| Recruiting | 2 | 45 | RoW | Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine | Wuhan Union Hospital, China, Renmin Hospital of Wuhan University | Locally Advanced Rectal Cancer | 12/24 | 12/27 | | |
NCT06285019: Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 65 | RoW | TOMOX-HAIC, Sintilimab, Bevacizumab | Fudan University | Hepatocellular Carcinoma | 12/24 | 12/25 | | |
NCT06256328: A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) |
|
|
| Recruiting | 2 | 210 | Japan, RoW | ONO-4578, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium, Nivolumab, Opdivo, Placebo | Ono Pharmaceutical Co. Ltd | Gastric Cancer | 11/25 | 12/27 | | |
NCT05024513: Biliary Drainage Plus HAIC in Locally Advanced pCCA |
|
|
| Recruiting | 2 | 127 | RoW | oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care, External biliary drainage | Peking University | Perihilar Cholangiocarcinoma | 12/24 | 12/25 | | |
| Recruiting | 2 | 214 | Europe | Regorafenib, panitumumab, Panitumumab, regorafenib | Gruppo Oncologico del Nord-Ovest, Bayer, Amgen | Colorectal Cancer | 12/24 | 06/25 | | |
NCT06143579: A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 48 | NA | FOLFOX-HAIC+Lenvatinib+Envolizumab, KN035 | Sun Yat-sen University | Potentially Resectable Hepatocellular Carcinoma | 03/25 | 12/26 | | |
NCT06153368: Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC |
|
|
| Not yet recruiting | 2 | 30 | RoW | Cadonilimab+mFOLFIRINOX, Cadonilimab+Oxaliplatin+ Irinotecan+ Leucovorin+ 5-fluorouracil | The First Affiliated Hospital with Nanjing Medical University | Pancreatic Cancer | 11/24 | 11/25 | | |
NCT04135690: HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial |
|
|
| Recruiting | 2 | 60 | RoW | Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib, systemic treatment | Sun Yat-sen University | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT05246982: HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | HLX07+HLX10+oxaliplatin+capecitabine, HLX07 | Shanghai Henlius Biotech | Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | 12/23 | 03/24 | | |
NCT04668365: Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma |
|
|
| Recruiting | 2 | 59 | RoW | Rituximab, RiTUXimab Injection, Zanubrutinib, Zanubrutinib Pill, Cyclophosphamide, Cyclophosphamide Injection, Epirubicin, Epirubicin Injection, Vincristine, Vincristine Injection, Prednisone, Prednisone Pill | Henan Cancer Hospital | Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation | 12/23 | 12/25 | | |
| Recruiting | 2 | 20 | RoW | Liposomal irinotecan | The First Affiliated Hospital with Nanjing Medical University | Pancreatic Ductal Adenocarcinoma | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 98 | RoW | Capecitabine, Oxaliplatin, External beam radiotherapy, Surgery, Watch and wait strategy | Sun Yat-sen University | Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III, Chemoradiation | 12/23 | 06/27 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
BJCC-R01, NCT04405206: Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer |
|
|
| Recruiting | 2 | 54 | RoW | Oxaliplatin, OXA, Capecitabine, Cape, intensity modulated radiotherapy, IMRT, DRE-Endoscopy-MRI-CEA, Nonoperative Management, NOM, Local excision, LE, Total Mesorectal Excision, TME, Quality of Life Questionnaires, QLQ | Beijing Cancer Hospital | Rectum Cancer | 12/23 | 12/23 | | |
NCT04715633: PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 53 | RoW | PD-1 inhibitor plus VEGF inhibitors, Camrelizumab plus Apatinib | Sun Yat-sen University, Guangdong Provincial People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine | Colorectal Cancer, Microsatellite Instability High | 12/23 | 12/24 | | |
NICE, NCT04744649: Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial |
|
|
| Recruiting | 2 | 110 | RoW | XELOX or SOX, Control group, JS001+XELOX or SOX, Experimental group and Exploratory group | Nanfang Hospital of Southern Medical University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Stomach Neoplasm | 12/23 | 12/24 | | |
NCT05935579: Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Durvalumab, Lenvatinib Oral Product, Chemotherapy | Peking Union Medical College Hospital | Biliary Tract Neoplasms, Immunotherapy | 12/23 | 12/24 | | |
NCT03406299: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 92 | RoW | Tegafur, S-1, Leucovorin, Folinic acid, Oxaliplatin, oxalic, Gemcitabine, Gemmis, Cisplatin | National Health Research Institutes, Taiwan | Biliary Tract Neoplasms | 12/23 | 12/23 | | |
TRIPLET, NCT04191889: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification |
|
|
| Recruiting | 2 | 47 | RoW | Hepatic Arterial Infusion combined with Apatinib and Camrelizumab | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | C-staged Hepatocellular Carcinoma in BCLC Classification | 12/23 | 12/25 | | |
NCT03403101: The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 2 | 65 | RoW | S1, Oxaliplatin, Irinotecan | Fudan University | Carcinoma, Pancreatic Ductal | 12/23 | 07/24 | | |
NCT04447092: Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 77 | RoW | Gemcitabine, Nab-paclitaxel, Pembrolizumab, Oxaliplatin, Leucovorin, Irinotecan, 5FU | Seoul National University Hospital | Pancreatic Cancer, Chemotherapy Effect | 12/24 | 12/25 | | |
NCT04609176: Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 64 | RoW | Camrelizumab plus Apatinib and SOX, Camrelizumab plus Apatinib | Peking University, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer | 12/23 | 12/24 | | |
ULTIMA, NCT04611724: A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer |
|
|
| Recruiting | 2 | 35 | RoW | FOLFIRINOX | Asan Medical Center, Green Cross Corporation, Boryung Pharmaceutical Co., Ltd | Urachal Cancer | 12/23 | 09/24 | | |
NCT04832776: FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases |
|
|
| Recruiting | 2 | 160 | RoW | Cetuximab, Bevacizumab, FOLFOXIRI | Fudan University | Liver Metastasis Colon Cancer | 12/23 | 12/25 | | |
| Recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/27 | | |
NCT05052931: Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Nab-paclitaxel combined with oxaliplatin and S-1 | Jianjun Yang, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/23 | 12/23 | | |
ChiCTR2100050872: Anlotinib Hydrochloride Combined with Chemotherapy as First-Line and Maintenance Therapy for Gastrointestinal Tumors with Unresectable Liver Metastasis: A Multi-Cohort, Multi-Center Trial (ALTER-G-001) |
|
|
| Recruiting | 2 | 101 | | Anlotinib and CAPEOX(oxaliplatin and capecitabine) ;Anlotinib and TP/DP(combination chemotherapy with paclitaxel and cisplatin) ;Anlotinib and standard first-line chemotherapy | Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastrointestinal Tumors with Unresectable Liver Metastasis | | | | |
ChiCTR2100053431: Raltitrexed + Oxaliplatin (SALOX) plus Bevacizumab as the First Line Treatment in Patients with Advanced Colorectal Cancer: An Open-Label, Multicenter, Prospective Study |
|
|
| Recruiting | 2 | 90 | | Raltitrexed 3 mg/m^2 + Oxaliplatin 130 mg/m^2 + Bevacizumab 7.5 mg/kg | Medical Oncology Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Self-funded | Colorectal cancer | | | | |
NCT05111444: Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 65 | RoW | Camrelizumab, Pyrotinib, Capecitabine, Oxaliplatin, Paclitaxel, S-1 | Fudan University | Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma | 12/23 | 06/24 | | |
ChiCTR2100054135: Exploratory clinical study of neoadjuvant treatment of MSS/pMMR locally advanced rectal cancer with sintilimab, anlotinib combined with XELOX by short-course radiotherapy |
|
|
| Not yet recruiting | 2 | 53 | | Sintilimab 200 mg ivgtt, Q3W, Anlotinib 8 mg PO QD D1-14 and chemotherapy XELOX for 6 cycles | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-funded | Rectal cancer | | | | |
NCT05077800: FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer |
|
|
| Recruiting | 2 | 70 | US | FOLFIRNINOX, Losartan, Cozaar, 9-ING-41 | Colin D. Weekes, M.D., PhD, Actuate Therapeutics Inc., Lustgarten Foundation | Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic | 12/25 | 07/26 | | |
NCT05311189: Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer |
|
|
| Not yet recruiting | 2 | 40 | NA | HLX10, Trastuzumab and Chemotherapy | Shanghai Zhongshan Hospital | HER2-positive Gastric Cancer | 12/23 | 12/24 | | |
ChiCTR2200058732: Perioperative chemotherapy plus trastuzumab and PD-1 antibody in HER2-positive locally advanced gastric, or gastro-esophageal junction cancer: an open-label, phase 2 trial |
|
|
| Recruiting | 2 | 88 | | oxaliplatin 130mg/m^2 ivdrip d1 q3w ;tegafur 40mg/m^2 bid po d1-14 q3w ;Trastuzumab 8mg/kg for the frist time，6mg/kg from the second time ivdrip q3w ;Cindillizumab 200mg ivdrip q3w | Yuanfang Li; Sun Yat-sen University CancerCenter, Innovent Biologics (Suzhou) Co., Ltd. | gastric, or gastro-esophageal junction cancer | | | | |
NCT04782791: Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | Nivolumab plus SOX, Nivo + SOX, Nivolumab, Nivo, Gastrectomy | Chinese PLA General Hospital | Gastric Cancer, Chemotherapy Effect | 12/23 | 05/24 | | |
ChiCTR2200063761: Efficacy and safety of FLOT regimen (docetaxel + oxaliplatin + leucovorin + fluorouracil) combined with apatinib and sintilimab in the first-line treatment of first-diagnosed stage IV gastric and gastroesophageal junction adenocarcinoma: a prospective, open-label, multicenter, single-arm clinical study |
|
|
| Recruiting | 2 | 40 | | FLOT + apatinib + sintilimab | Lanzhou University Second Hospital; Lanzhou University Second Hospital, self-funded | Stage IV gastric/gastroesophageal junction adenocarcinoma | | | | |